Bristol-Myers Squibb & California Institute for Biomedical Research (Calibr) Sign Worldwide Research Collaboration & License ...
January 05 2015 - 8:00AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) and the California
Institute for Biomedical Research (Calibr) announced today they
have entered into a worldwide research collaboration to develop
novel small molecule anti-fibrotic therapies, and an exclusive
license agreement that allows Bristol-Myers Squibb to develop,
manufacture and commercialize Calibr’s preclinical compounds
resulting from the collaboration.
“Bristol-Myers Squibb’s collaboration with Calibr further
strengthens our Specialty portfolio and advances the company’s
fibrotic diseases pipeline with the addition of this promising
program,” said Carl Decicco, Ph.D., Head of Discovery, R&D,
Bristol-Myers Squibb. “Calibr’s innovative discovery program in
fibrosis represents an opportunity to develop new treatment
approaches for patients.”
“Progressing our small molecule anti-fibrotic program toward the
clinic represents a critical step in our mission to deliver
therapies for unmet medical needs to patients,” said Peter G.
Schultz, Ph.D., Institute Director and Founder of Calibr. “We are
delighted to accelerate these efforts by partnering with
Bristol-Myers Squibb.”
Identifying novel medicines to halt or slow the progression of
fibrotic disease and improve upon the current standard of care is a
key part of Bristol-Myers Squibb’s R&D strategy. Calibr, an
independent, not-for-profit organization established to accelerate
the translation of basic biomedical discoveries into innovative new
medicines, brings to the collaboration substantial expertise in
identifying and optimizing small molecules with anti-fibrotic
activity through its high-throughput screening, target
identification, and preclinical drug discovery infrastructure.
Bristol-Myers Squibb is committed to addressing the unmet need
in fibrosis, a strategic area of focus for the company, by
identifying novel medicines to halt or slow the progression of
fibrotic disease. Among the assets in Bristol-Myers Squibb’s
fibrosis portfolio are BMS-986020, a lysophosphatidic acid 1 (LPA1)
receptor antagonist in Phase 2 development for the treatment of
idiopathic pulmonary fibrosis (IPF), and a CCR2/5 dual antagonist
in Phase 2 development for diabetic kidney disease. In November,
2014, Bristol-Myers Squibb and Galecto Biotech AB announced,
together with the Galecto shareholders, an agreement that provides
Bristol-Myers Squibb the exclusive option to acquire Galecto
Biotech AB and gain worldwide rights to its lead asset TD139, a
novel inhaled inhibitor of galectin-3 in Phase 1 development for
the treatment of IPF and other pulmonary fibrotic conditions.
Bristol-Myers Squibb and Calibr anticipate that the transaction
will close during the first quarter of 2015. Closing of the
transaction is subject to customary closing conditions, including
clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Financial terms of the agreement were not disclosed.
About California Institute of Biomedical Research
The California Institute for Biomedical Research (Calibr) is an
independent, not-for-profit organization established in 2012 with
the goal of accelerating the translation of basic biomedical
research to new therapies that address unmet medical needs.
Calibr’s research interests span a large range of human diseases,
including cancer, autoimmunity and inflammatory diseases, metabolic
and cardiovascular diseases, infectious and neglected diseases, as
well as age-related and degenerative diseases.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit www.bms.com or follow us on Twitter at
http://twitter.com/bmsnews.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking
statement can be guaranteed. Among other risks, there can be
no guarantee that the investigational compounds discussed in this
release will be successfully developed or approved for any of the
indications described in this release or that the transaction will
close within the timeframe described in this
release. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2013 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
Bristol-Myers SquibbMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorInvestors:Ranya Dajani,
609-252-5330ranya.dajani@bms.comorRyan Asay,
609-252-5020ryan.asay@bms.comorCalibrMatt Tremblay,
858-242-1005mtremblay@calibr.org
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024